Verrica Pharmaceuticals
VRCA
52 hedge funds and large institutions have $144M invested in Verrica Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 22 increasing their positions, 7 reducing their positions, and 3 closing their positions.
333% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 3
214% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 7
24% more funds holding
Funds holding: 42 → 52 (+10)
5% more capital invested
Capital invested by funds: $137M → $144M (+$7.3M)
0.03% less ownership
Funds ownership: 3.6% → 3.57% (-0.03%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
+$769K |
| 2 |
Two Sigma Investments
New York
|
+$610K |
| 3 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
+$563K |
| 4 |
BlackRock
New York
|
+$472K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$425K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FI
Fosun International
Hong Kong,
China
|
-$5.59M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.9M |
| 3 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$1.1M |
| 4 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$399K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$116K |
VRCA Hedge Fund Activity: Q4 2019 in Review
52 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q4 2019, worth a combined $144M — up 5.3% from $137M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new VRCA positions and 3 closed out — a net gain of 10 holders — while 22 added to existing stakes and 7 trimmed.
The largest buyer was Squarepoint, opening a new position worth an estimated $769K. The largest seller was Fosun International, cutting an estimated $5.59M.
- 52 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q4 2019, up from 42 in Q3 2019.
- Funds reported $144M of Verrica Pharmaceuticals stock for Q4 2019, up 5.3% quarter-over-quarter.
- 13 funds opened new Verrica Pharmaceuticals positions in Q4 2019 and 3 closed out, a net change of +10 holders.
- The largest Verrica Pharmaceuticals buyer in Q4 2019 was Squarepoint, an estimated $769K added.
- The largest Verrica Pharmaceuticals seller in Q4 2019 was Fosun International, an estimated $5.59M sold.
Based on aggregated 13F filings for Q4 2019.